A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs AG 10 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; First in man
- Sponsors Eidos Therapeutics
- 09 Nov 2017 According to an Eidos Therapeutics media release, data from this trial will be presented at the American Heart Association's (AHA) 2017 Annual Scientific Sessions.
- 28 Sep 2017 According to an Eidos Therapeutics media release, dosing of the first healthy adult cohort has commenced.
- 22 Sep 2017 Status changed from planning to recruiting.